Chimeric Therapeutics Ltd (ASX:CHM) has had the first CLTX CAR T abstract accepted for presentation at the prestigious annual meeting of the American Society of Clinical Oncology (ASCO), which is being virtually held from June 4-8.
The abstract highlights City of Hope’s phase 1 clinical trial design and objectives for Chlorotoxin CAR T (CLTX CAR T), a first and potentially best in class CAR T cell therapy that has the potential to address the high unmet medical need of patients with recurrent or progressive glioblastoma.
City of Hope, a world-renowned cancer research and treatment centre near Los Angeles, is leading the trial.
Details of the abstract presentation are:
- Section: Trial in Progress: Developmental Therapeutics - Immunotherapy;
- Abstract #: TPS2662; and
- Title: A phase 1 study to evaluate chimeric antigen receptor (CAR) T cells incorporating a chlorotoxin tumour-targeting domain for patients with MMP2+ Recurrent or progressive glioblastoma (NCT04214392). Badie, B., et al.
The abstract release will be online on May 19, 2021, at 5:00 PM EDT at ASCO.org.
CHLOROTOXIN CAR T therapy
Chlorotoxin CAR T (CLTX CAR T) is a first and potentially best in class CAR T therapy that has the potential to address the high unmet medical need of patients with recurrent or progressive glioblastoma.
Research to develop the intellectual property covering this CAR T cell therapy took place at City of Hope.
CLTX CAR T cells uniquely utilise chlorotoxin (CLTX), a peptide component of scorpion venom, as the tumour-targeting component of the chimeric antigen receptor (CAR).
CLTX and CLTX CAR T cells have been shown in preclinical models to bind more broadly and specifically to GBM cells than other targeting domains like EGFR, HER2 or IL-13.
In preclinical models, CLTX CAR T cells also demonstrated potent antitumor activity against glioblastoma while not exhibiting any off-tumour recognition of normal human cells and tissues, indicating a potentially optimal safety and efficacy profile